Image-guided radiotherapy for locally advanced head and neck cancer
- 1Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
- 2Division of Hematology/Oncology, University of Arizona, Tucson, AZ, USA
- 3Department of Radiation Oncology, Centre Val d’Aurelle, Montpellier, France
- 4Department of Radiation Oncology, Lindenhofspital, Bern, Switzerland
- 5Department of Radiation Oncology, University Hospitals of Geneva, Geneva, Switzerland
- 6Department of Oral Maxillofacial Surgery, The Ministry and Education of Ukraine, Kiev, Ukraine
- 7Department of Radiation Oncology, University of West Virginia, Morgantown, WV, USA
- 8Southwest PET Institute, Tucson, AZ, USA
- 9Department of Radiation Oncology, Hirslanden Radiation Oncology Institute, Lausanne, Switzerland
- 10Department of Radiology, University of Arizona, Tucson, AZ, USA
- 11Florida Radiation Oncology Group, Palatka, FL, USA
- 12Department of Radiation Oncology, Marshfield Clinic, Marshfield, WI, USA
- 13Department of Radiation Oncology, Louisiana State University, Shreveport, LA, USA
Treatment of locally advanced head and neck cancer remains a challenge because of the head and neck complex anatomy and the tumor invasion to the adjacent organs and/or metastases to the cervical nodes. Postoperative irradiation or concurrent chemoradiation may lead to damage of radiosensitive structures such as the salivary glands, mandible, cochlea, larynx, and pharyngeal muscles. Xerostomia, osteoradionecrosis, deafness, hoarseness of the voice, dysphagia, and aspiration remain serious complications of head and neck irradiation and impair patient quality of life. Intensity-modulated and image-guided radiotherapy by virtue of steep dose gradient and daily imaging may allow for decreased radiation of the organs at risk for complication while preserving loco-regional control.
Treatment of Locally Advanced Head and Neck Cancer
Treatment of locally advanced head and neck cancer remains a challenge because of the high rate of loco-regional failures and the potential for serious complications following treatment. The tumor frequently invades adjacent organs and/or regional neck nodes. Standard of care has been either postoperative irradiation or concurrent chemoradiation (1). Regardless of the modality chosen, serious complications may occur because of the presence of radiosensitive organs such as the salivary glands, cochlea, mandible, larynx, and pharyngeal muscles in the radiation field. Xerostomia, deafness, osteoradionecrosis, dysphagia, weight loss, chronic hoarse voice, and aspiration are potential long-term complications of radiation treatment with conventional radiotherapy techniques. Intensity-modulated radiotherapy (IMRT) has been introduced to decrease the toxicity of irradiation because of the steep dose gradient allowing for sparing of radiosensitive organs. Randomized studies have demonstrated significant sparing of the parotid glands following IMRT of head and neck cancer and decreased severity of the xerostomia with improvement of patient quality of life (QOL) (2, 3). However, a significant amount of normal tissues is still irradiated because the inclusion of the tumor and areas at high risk for invasion with a large rim of normal tissue called planning target volume or PTV, to avoid marginal miss. Recently, image-guided radiotherapy (IGRT) by combining the steep dose gradient of IMRT and daily imaging may potentially improve further the toxicity of head and neck irradiation because of the possibility of safe PTV reduction given the reduced inter-fraction movement through daily imaging.
Significant reduction of spinal cord dose may be achieved with IGRT compared to IMRT by a reduced PTV margin (4). However, the flip side of IGRT is also the risk of under-dosing the tumor if the target area is not adequately outlined. Thus, pre-treatment imaging to meticulously delineate the tumor and areas at risk of invasion is a critical component for the success of IGRT.
Imaging Studies Critical for IGRT Planning
Positron-emission tomography (PET) scan or PET-computed tomography (PET-CT) allows accurate delineation of the tumor and cervical lymph nodes that can be incorporated into the planning CT. PET-CT is superior to CT for tumor imaging because of its ability to detect the tumor metabolic activity in addition to its anatomic location. In a study of 102 unresectable head and neck cancer, PET-CT significantly changed the staging and management of these patients compared to CT alone (5). Twelve patients had modifications of the radiotherapy planning following review of their PET-CT. In another study of 20 patients with oropharyngeal cancers, the incorporation of PET-CT into radiotherapy planning prevented marginal miss in two patients (6). The ability of PET-CT for better tumor delineation compared to CT for radiotherapy planning was also corroborated in other studies (7, 8). Thus, PET-CT should be included in the planning for head and neck IGRT.
Although PET-CT is the diagnostic imaging of choice for head and neck cancer IGRT, magnetic resonance imaging (MRI) also plays a critical role when there is suspicion of nerves infiltration, base of skull or parapharyngeal space invasion by the tumor given its better soft tissue discrimination compared to CT. For patients with nasopharyngeal cancer, MRI is complementary to PET-CT because of the tumor location with high risks for intracranial invasion through the skull base foramen and parapharyngeal extension (9, 10). In addition head and neck MRI may also have a prognostic value for survival after head and neck irradiation of nasopharyngeal cancer (11).
Image-Guided Radiotherapy Potential for Parotid Gland Preservation
Xerostomia remains one of the most common complications of head and neck cancer Irradiation and may severely affect the QOL of patients. Xerostomia results from apoptosis of the acinar glands secondary to radiation and its severity is proportional to the radiation dose to the parotid glands (12).
Compared to the three-dimensional conformal radiotherapy technique (3D-CRT), IMRT may significantly reduce radiation dose to the parotid glands because of the steep dose gradient. Mean dose to the parotids is usually kept around 26 Gy to allow recovery of the saliva following head and neck irradiation. However, if only one parotid gland can be spared from radiation, current recommendation is to keep mean parotid dose at 20 Gy or lower (13). A recent study suggested that preservation of the contralateral parotid gland may lead to improvement of patient QOL following head and neck cancer irradiation. Among 31 patients with head neck cancer treated with IMRT, there was significant preservation of salivary flow and better QOL as measured by QOL questionnaires if the contralateral parotid gland can be preserved because of less sticky saliva (14). Preliminary experience suggests that IGRT may preserve salivary function and QOL without compromising target coverage. In a study of 76 patients treated with IGRT for head and neck cancer, excellent loco-regional control was obtained as the gross tumor was treated to 70.5 Gy in 2.2–2.3 Gy/fraction while most of the patients were able to preserve a good QOL because of parotid preservation (15). In another study of parotid preservation, IGRT can significantly decrease the mean contralateral parotid gland dose to 14 Gy without compromising target coverage, suggesting that IGRT may further improve patient QOL compared to IMRT (16).
Potential of IGRT for Hearing Preservation
Hearing loss commonly occurred following concurrent head and neck chemoradiation. A significant proportion of head and neck patients had baseline hearing deficit prior to radiation related to their age. Cisplatin can cause hearing loss which is dose-dependent and may exacerbate the elderly patients hearing deficits. When cisplatin is combined with radiotherapy, the hearing loss may worsen because of the radiosensitization effects of cisplatin on the normal cochlea cells. The threshold for hearing deficit ranges from 10 to 13 Gy when radiotherapy is combined with chemotherapy and affects mainly the high frequency range (>4,000 Hz) (17). However, severe deafness may occur when cochlea radiation dose exceeds 47 Gy because the low frequencies range (<3,000 Hz) is then also affected (18). Deafness is a handicap and may lead to social isolation and poor QOL. In addition, it may affect the patient gainful employment because of the difficulty to communicate at work. Thus, lowering cochlea dose below the threshold for hearing deficit may preserve the patients’ hearing and conserve their QOL. Compared to 3D-CRT, IMRT may decrease radiotherapy dose to the cochlea and provide better hearing preservation (19). Mean cochlea dose reported in the literature for patients with head and neck cancer undergoing IMRT ranged from 16 to 55 Gy. Preliminary data for IGRT of head and neck cancer for cochlea sparing is encouraging. In a study of 52 patients who had IGRT for locally advanced head and neck cancer, mean cochlea dose was reduced to 6–6.5 Gy which is below the threshold for radiotherapy damage without compromising target volume coverage (20). Thus, hearing preservation with IGRT is feasible and needs to be investigated in future prospective studies of head and neck cancer.
Potential of IGRT for Mandibular Sparing
Osteoradionecrosis remains one of the most feared complications of head and neck cancer irradiation because of its effect on patient QOL. In severe cases of osteoradionecrosis unresponsive to conservative management, resection of the damaged bone may result in severe alteration of speech, chewing, and swallowing. The risk of radionecrosis is related to the volume of normal bone radiated to high radiation dose. Damage of the microvasculature irrigating the mandible may lead to decreased blood flow, poor wound healing, and ultimately necrosis. Mandibular radionecrosis usually occurs when the mandible dose exceeds 66 Gy (21). The prevalence of osteoradionecrosis ranges from 5 to 7% in head and neck cancer patients treated with the conventional fractionation (1.8–2 Gy/fraction) and 3D-CRT. The risk of radionecrosis may be reduced with IMRT because of the sharp dose gradient allowing for reduction of the volume of normal bone radiated to a high dose. The reported prevalence of osteoradionecrosis ranges from 1 to 5% depending on the anatomic site of the cancer as cancers of the oral cavity usually require treating a large of volume of the mandible to a high radiation dose (22, 23). The IGRT technique may further decrease radiation dose to the mandible and thus the risk of radionecrosis. In a study of 83 head and neck cancer patients of various anatomic sites treated with IMRT (17) and IGRT (66), only one patient developed radionecrosis (24). Thus, IGRT may be a promising technique for mandibular preservation in future clinical trials.
Potential of IGRT to Prevent Laryngeal Edema in Non-Laryngeal and Non-Hypopharyngeal Head and Neck Cancer
Laryngeal edema and resulting dysphonia commonly occur following head and neck cancer radiation when the laryngeal dose exceeds 43.5 Gy (25). The dysphonia severity is proportional to the radiation dose and related on the abnormal cord vibrations caused by the edema which may be persistent up to 72 months after radiation (26). Chronic hoarseness of the voice may impair patient QOL or affect their professional activity if the patient depends on the quality of his voice to make a living. Laryngeal edema is unavoidable when the tumor is located in the larynx or hypopharynx because of the high radiation dose required for cure (70 Gy). When the tumor is located in other anatomic sites, shielding of the larynx with a midline block would significantly decrease radiation dose to the larynx and prevent the risk of laryngeal edema. However, in the presence of cervical lymph nodes, a laryngeal shield may under-dose the cervical lymph nodes leading to an increased risk of regional recurrence. Whole field head and neck IMRT is usually recommended in the presence of neck node metastases to avoid geographic miss. Compared to whole field head and neck IMRT, IGRT can significantly reduce radiation dose to the larynx in patients with non-laryngeal and non-hypopharyngeal head and neck cancers (27). Preliminary results suggest that IGRT may also reduce the risk of laryngeal edema and effectively preserve patient voice following head and neck radiation (28).
Potential of IGRT to Reduce Aspiration Risk Following Radiation for Non-Laryngeal and Non-Hypopharyngeal Head and Neck Cancer
Aspiration is a life-threatening complication of a head and cancer irradiation because of the risk of pneumonia and sepsis. Aspiration commonly occurs following head and neck cancer irradiation because of damage to the pharyngeal constrictor muscles. Aspiration risk is proportional to radiation dose to the pharyngeal muscles. Even though there are still controversies about which pharyngeal muscles are critical for the development of aspiration, 32% of the patients developed aspiration when the dose to the inferior pharyngeal muscles exceeds 52 Gy (29). Thus, patients with laryngeal and hypopharyngeal cancer are at highest risk of aspiration following head and neck cancer irradiation. However, a high rate of aspiration is still observed following radiation of non-laryngeal and non-hypopharyngeal head and neck cancers. Aspiration rates ranged from 16 to 54% following non-laryngeal and non-hypopharyngeal cancer irradiation with 3D-CRT and whole field IMRT (30, 31). Whole field IGRT reduces significantly the risk of aspiration for these patients. Only 2 out of 48 patients developed minimal aspiration which resolved with swallowing therapy following IGRT for non-laryngeal and non-hypopharyngeal head and neck cancer (32). Thus, IGRT is a promising technique to reduce the risk of aspiration and to improve patient QOL in head and neck cancer patients.
Effectiveness of IGRT for Loco-Regional Control in Patients with Head and Neck Cancers
Preliminary clinical experiences of IGRT for head and neck cancers have been very encouraging. Excellent loco-regional control and survival have been achieved for various anatomic head and neck cancer sites. In a study of 19 patients with locally advanced oral cavity cancer who received postoperative irradiation with IGRT, the 2-year survival and loco-regional control were 94 and 92%, respectively (33). In another study of 28 patients who underwent concurrent chemotherapy and IGRT for locally advanced nasopharyngeal cancer, the 3-year survival and loco-regional control were respectively 83.5 and 88.4% respectively (34). Similar high rates of loco-regional control were also observed for oropharyngeal and laryngeal cancers (35, 36). Because of the small number of patients and the short follow-up, these studies should be interpreted with caution but they may be helpful for the design of future prospective studies of head and neck cancer IGRT.
Image-guided radiotherapy for head and neck cancer is a promising technique of radiation because of the potential for normal organ sparing without compromise of target coverage. Preliminary clinical results suggest that the dosimetric advantages of IGRT may be translated into excellent loco-regional control for patients with head and neck cancer. Further prospective studies with a large number of patients should be performed to verify this hypothesis.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
1. Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV non-metastatic squamous cell head and neck cancer. Br J Cancer (2005) 93:279–86. doi:10.1038/sj.bjc.6602696
2. Gupta T, Agarwall J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiotherapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol (2012) 104:343–8. doi:10.1016/j.radonc.2012.07.001
3. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PASSPORT): a phase 3 multicentre randomized controlled trial. Lancet Oncol (2011) 12:127–36. doi:10.1016/S1470-2045(10)70290-4
4. Schwarz M, Giske K, Stoll A, Nill S, Huber PE, Debus J, et al. IGRT versus non-IGRT for postoperative head and neck IMRT patients: dosimetric consequences arising from a PTV reduction. Radiat Oncol (2012) 7:133. doi:10.1186/1748-717X-7-133
5. Abramyuk A, Appold S, Zophel K, Baumann M, Abolmaali N. Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol (2013) 189:197–201. doi:10.1007/s00066-012-0283-0
6. Chatterjee S, Frew J, Mott J, McCallum H, Stevenson P, Maxwell R, et al. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi-Art machine: final results of the VortigERN study. Clin Oncol (2012) 24:e173–9.
7. Delouya G, Igidbashian L, Houle A, Belair M, Boucher L, Cohade C, et al. 18F-FDG-PET imaging in radiotherapy volume delineation in treatment of head and neck cancer. Radiother Oncol (2011) 101:362–8. doi:10.1016/j.radonc.2011.07.025
8. Garg MK, Glantzman J, Kalnicki S. The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer. Semin Nucl Med (2012) 42:320–7. doi:10.1053/j.semnuclmed.2012.04.005
9. Liao XB, Mao YP, Liu LZ, Tang LL, Sun Y, Wang Y, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography. Int J Radiat Oncol Biol Phys (2008) 72:1368–77. doi:10.1016/j.ijrobp.2008.03.017
11. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, et al. Prognostic values and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MRI imaging. Radiology (2010) 257:151–7. doi:10.1148/radiol.10100033
12. Roesink JM, Moerland MA, Batterman JJ, Hordijk G, Terhaard CHJ Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head and neck region. Int J Radiat Oncol Biol Phys (2001) 4:938–46. doi:10.1016/S0360-3016(01)01717-5
13. Deasy JO, Moisenko V, Marks L, Chao KSC, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 76:S58–63. doi:10.1016/j.ijrobp.2009.06.090
14. Chen WC, Lai CH, Lee TF, Hung CH, Liu KC, Tsai MF, et al. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlation with parotid dose and quality of life. Oral Oncol (2013) 49:42–8. doi:10.1016/j.oraloncology.2012.07.004
15. Voordeckers M, Farrag A, Everaert H, Tournel K, Storme G, Verellen D, et al. Parotid sparing with helical tomotherapy in head and and neck cancer. Int J Radiat Oncol Biol Phys (2012) 84:443–448. doi:10.1016/j.ijrobp.2011.11.070
16. Nguyen NP, Vos P, Vinh-Hung V, Ceizyk M, Smith-Raymond L, Stevie M, et al. Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer. BMC Cancer (2012) 12:175. doi:10.1186/1471-2407-12-175
17. Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensori-neural hearing loss in head and neck cancer patients. Int J Radiat Oncol Biol Phys (2009) 73:779–88. doi:10.1016/j.ijrobp.2008.05.040
18. Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys (2009) 73:1335–42. doi:10.1016/j.ijrobp.2008.07.034
19. Petsuksiri J, Sermsree A, Thephamongkhol K, Keskool P, Thongvai K, Chansilpa Y, et al. Sensorineural hearing loss after concurrent chemoradiotherapy for head and neck cancer. Radiat Oncol (2011) 6:19. doi:10.1186/1748-717X-6-19
20. Nguyen NP, Smith-Raymond L, Vinh-Hung V, Sloan D, Davis R, Vos P, et al. Feasibility of tomotherapy to spare the cochlea from excessive radiation in head and neck cancer. Oral Oncol (2011) 47:414–9. doi:10.1016/j.oraloncology.2011.03.011
22. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancer. Laryngoscope (2009) 73:1096–103. doi:10.1016/j.ijrobp.2008.05.024
23. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer (2008) 113:497–507. doi:10.1002/cncr.23578
24. Nguyen NP, Vock C, Chi A, Ewell L, Vos P, Mills M, et al. Effectiveness of intensity-modulated and image-guided radiotherapy to spare the mandible from excessive radiation. Oral Oncol (2012) 48:653–7. doi:10.1016/j.oraloncology.2012.01.016
26. Hamdan A, Geara F, Rameh C, Husseini HT, Eid T, Fuleihan N. Vocal changes following radiotherapy to the head and neck for non-laryngeal tumors. Eur Arch Otorhinolaryngol (2009) 266:1435–9. doi:10.1007/s00405-009-0950-7
27. Nguyen NP, Ceizyk M, Vos P, Vinh-Hung V, Davis R, Desai A, et al. Effectiveness of image-guided radiotherapy for laryngeal sparing in head and neck cancer. Oral Oncol (2010) 46:283–6. doi:10.1016/j.oraloncology.2010.01.010
28. Nguyen NP, Abraham D, Desai A, Betz M, Davis R, Sroka T, et al. Impact of image-guided radiotherapy to reduce laryngeal edema following treatment for non-laryngeal and non-hypopharyngeal head and neck cancer. Oral Oncol (2011) 47:900–4. doi:10.1016/j.oraloncology.2011.06.004
29. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 72:1110–8.
30. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng FM, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancers. J Clin Oncol (2010) 28:2732–8. doi:10.1200/JCO.2009.24.6199
31. Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Nguyen PD, et al. Analysis of factors influencing aspiration rates following chemoradiation for head and neck cancer. Br J Radiol (2009) 82:675–80. doi:10.1259/bjr/72852974
32. Nguyen NP, Smith-Raymond L, Vinh-Hung V, Vos P, Davis R, Desai A, et al. Feasibility of Tomotherapy based image-guided radiotherapy to reduce aspiration risk in patients with non-laryngeal and non-hypopharyngeal head and neck cancer. PLoS One (2013) 8:e56290.
33. Hsieh C, Kuo Y, Liao L, Hu K, Lin S, Lin Y, et al. Image-guided intensity-modulated radiotherapy with helical tomotherapy for postoperative high risk oral cavity cancer. BMC Cancer (2011) 11:37. doi:10.1186/1471-2407-11-37
34. Shueng PW, Shen BJ, Wu LJ, Liao LJ, Hsiao CH, Lin YC, et al. Concurrent image-guided guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. Radiat Oncol (2011) 6:95. doi:10.1186/1748-717X-6-95
35. Nguyen NP, Ceizyk M, Vos P, Betz M, Chi A, Almeida F, et al. Feasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancers. PLoS ONE (2013) 8:e60268. doi:10.1371/journal.pone.0060268
36. Nguyen NP, Chi A, Betz M, Almeida F, Vos P, Davis R, et al. Feasibility of intensity-modulated and image-guided radiotherapy for functional organ preservation in locally advanced laryngeal cancer. PLoS ONE (2012) 7:e42729. doi:10.1371/journal.pone.0042729
Keywords: head and neck cancer, image-guided radiotherapy, preservation of radiosensitive organs
Citation: Nguyen NP, Kratz S, Lemanski C, Vock J, Vinh-Hung V, Gorobets O, Chi A, Almeida F, Betz M, Khan R, Godinez J, Karlsson U and Ampil F (2013) Image-guided radiotherapy for locally advanced head and neck cancer. Front. Oncol. 3:172. doi: 10.3389/fonc.2013.00172
Received: 24 May 2013; Accepted: 17 June 2013;
Published online: 08 July 2013.
Edited by:Kwan-Hwa Chi, Shin-Kong Wu Ho-Su Memorial Hospital, Taiwan
Reviewed by:Seong Ki Mun, Virginia Tech, USA
Kai-Lin Yang, Shin-Kong Wu Ho-Su Memorial Hospital, Taiwan
Copyright: © 2013 Nguyen, Kratz, Lemanski, Vock, Vinh-Hung, Gorobets, Chi, Almeida, Betz, Khan, Godinez, Karlsson and Ampil. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Nam P. Nguyen, Department of Radiation Oncology, University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724-5081, USA e-mail: email@example.com